



4TH ANNUAL CONGRESS

Liquid Biopsy

20 – 22 October 2022 | Miami, Florida

Full Congress **PROGRAM**



www.islb.info/congress-2022



#ISLB2022

Congress Partners

ISLB 2022 would like to thank our generous sponsors:

Diamond



Platinum



FOUNDATION
MEDICINE



Silver



Signatera™
Residual disease test (MRD)

ThermoFisher
SCIENTIFIC

REGENERON
science to medicine®



EMD
SERONO

Bronze



4TH ANNUAL CONGRESS
Liquid Biopsy
20 - 22 October 2022 | Miami, Florida

Full Congress Program
www.islb.info/congress-2022

Table of Contents

Congress Partners.....	2
Welcome Message	4
Host Organization.....	5
Association & Committee	6
General Congress Information	7
Venue Floorplan.....	9
Exhibit & Poster Hall Information.....	10
Exhibitor Listing.....	11
Program at a Glance	16
Full Congress Program.....	17
ISLB Awards Lectures.....	28
Official Networking Events	29
Multidisciplinary Stakeholder Workshop.....	30
Posters	31
Save the Date for ISLB 2023.....	36



Welcome Message



It is our distinct pleasure to invite you to attend our 4th Annual ISLB Congress. This meeting will be held October 20-22, 2022 in Miami, Florida.

The meeting will bring together world experts in the field of Liquid Biopsy who will share their latest advances in the clinical field. During the event, all the most relevant aspects of clinical application and translational research on liquid biopsy will be presented. The congress is also giving possibility of discussions in each session, an extraordinary opportunity to share expertise and create networking.

Following the extraordinary participation and incredible impact of the last two virtual congresses with over 20K visits to the website, we are also planning on adding virtual or on demand elements for delegates at home. Increasing in this way, the possibility to have access to a high-level education.

ISLB has decided to structure the event under the same characteristics around a cutting-edge scientific agenda based on: Advancements in Liquid biopsy: Discovery, Diagnostics and Clinical Applications.

The annual ISLB 2022 Congress aims to address the principal advances in the world of the LB. The

congress will approach this from both the point of view of fundamental studies, as well as the more prevalent clinical and translational trials.

In this context, the scope of the program will focus on various sessions including:

- 💧 Basic research in Liquid Biopsy
- 💧 Liquid Biopsy advances in the last decade
- 💧 Translational research in Liquid Biopsy
- 💧 Current clinical application of Liquid Biopsy
- 💧 Expanding clinical application of Liquid Biopsy
- 💧 Future of Liquid Biopsy
- 💧 Liquid Biopsy clinical application challenges and opportunities worldwide
- 💧 ISLB Award lectures

We are excited to welcome you to Miami!



Christian Rolfo
President of ISLB on behalf of
the Executive Committee

Host Organization



The International Society of Liquid Biopsy (ISLB) is the first international professional organization committed to the improvement and implementation of liquid biopsies in clinical routine practice and the promotion of a multidisciplinary approach for the diagnosis and treatment of cancer patients based on the use of liquid biopsies.

ISLB was founded in 2017 in Granada, in Spain. Our aim is to join healthcare professionals, mainly oncologists and those who adopted liquid biopsies as a new clinical tool.

We are pleased to welcome liquid biopsies professionals all over the world. We would like to be the link among stakeholders in the liquid biopsies theme.

Our education and information program is based on an integrated multidisciplinary approach to reach an advanced cancer research.

We seek to remove obstacles that limit liquid biopsies implementation in the routine clinical practice, with the aim to expand liquid biopsies adoption all over the world.

Association and Committee

Executive Committee



Christian Rolfo
USA (ISLB President)



Maria José Serrano
Spain (ISLB Vice President)



Umberto Malapelle
Italy (ISLB Scientific Secretary)



Eloisa Jantus Lewintre
Spain (ISLB Treasurer)



David R. Gandara
USA (ISLB CMO)



Massimo Cristofanilli
USA (ISLB Past President)

Local Organizing Committee



Dr. Luis E. Raez
USA (LOC Co-Chair)



Dr. Maria E. Arcila
USA (LOC Co-Chair)

General Congress Information



Venue

Sheraton Miami Airport Hotel & Executive Meeting Center

Address: 3900 NW 21st St, Miami, FL 33142, United States

Phone: +1 305-871-3800

Access / Security

Name badges will be provided to all attendees, sponsors, and exhibitors and will be available for pick up at the Registration Desk (see venue map). Please wear your badge at all times as it is your admission to all Congress sessions, Exhibit & Poster Hall, and non-ticketed social events. Any lost badges will incur a 50 USD reprint fee.

Language

The official language of ISLB 2022 is English. All sessions will be conducted in English.

Parking

The Sheraton Miami Airport Hotel offers onsite parking and valet services. Daily Parking is available for 27 USD and Valet 32 USD per day.

Lost Property

Please report any lost or unattended items immediately to the ISLB 2022 Registration Desk. Should you lose anything while at the ISLB 2022 Congress, please enquire at the Registration Desk where any recovered lost property will be held. At the end of the congress, all unclaimed lost and found items will be given to The Sheraton Miami Airport Hotel & Executive Meeting Center.

Refreshment Breaks

Location: Clipper Ballroom & Terrace and Clipper Ballroom Pre-Function Spaces

October 21

AM Refreshment Break 10:00 – 10:30

PM Refreshment Break 15:05 – 15:35

October 22

AM Refreshment Break 10:45 – 11:00

PM Refreshment Break 13:30 – 14:15

General Congress Information

Registration Hours

Location: Meeting Level, Foyer

October 20	11:30 – 19:00
October 21	7:30 – 19:30
October 22	7:30 – 15:30

Wi-Fi

Complimentary Wireless Internet is included in the congress areas

Network Name:
Sheraton Meeting

Mobile App

Supported by



Please download the ISLB 2022 Mobile App to access the most up-to-date scientific program, contact fellow delegates, build a personalized schedule for the conference, and to increase your onsite and virtual engagement & participation.

Please download and install the mobile app to your device by scanning the following QR code or via the direct link below:

App Store:



<https://itunes.apple.com/us/app/the-event-app-by-eventsair/id1142851582?ls=1&mt=8>

Play Store:



<https://play.google.com/store/apps/details?id=com.eventsair.attendeeapp>

Alternatively, please search for the EventsAir mobile App in your respective App Store. Once you have downloaded the app, enter the following event code (all lower-case text) when first opening the app: **islb** (Every registered delegate has received a personalized PIN number via email.)

Onsite Health and Safety

The health and safety of all those who attend ISLB 2022 is paramount. Our commitment is to provide a safe and comfortable environment for all. And so, with each of your well-being in mind, we are implementing the following COVID-19 Safety Policy for all Congress attendees:

- 💧 Mask Policy: Masks are to be worn by all attendees of the Congress while inside the conference center, except while eating or drinking
- 💧 Vaccination Policy: All attendees of the Congress are to be vaccinated according to the National Standards of the attendee's country

By registering to attend, you agree that you will not attend if you have any COVID-19 symptoms. If during your attendance, you develop any COVID-19 symptoms, you will immediately:

- 💧 Self-isolate
- 💧 Comply with all local/national government restrictions
- 💧 Inform the ISLB 2022 Congress Secretariat by email at islb2022-registration@icsevents.com

These terms and conditions are subject to change prior to the Congress.

ISLB and their suppliers will, in their best effort, provide a safe environment to meet. It is expected that all participants will follow the measures to help reduce the risk.

By registering for ISLB 2022 and choosing to attend ISLB 2022 in person, you agree that there is a risk of contracting COVID-19 even with all the safety measures in place. You are attending at your own risk and the ISLB 2022 Congress Secretariat and its contractors cannot be held responsible if you contract COVID-19 either before, during, or after returning from the congress.

Venue Floorplan

Venue

Sheraton Miami Airport Hotel & Executive Meeting Center


Address: 3900 NW 21st St, Miami, FL 33142, United States

Phone: +1 305-871-3800



Sheraton®

MIAMI AIRPORT
HOTEL & EXECUTIVE MEETING CENTER



PLENARY ROOM



PATIENT ADVOCATE LOUNGE



FACULTY LOUNGE



POSTER AREA



EXHIBIT AREA



REGISTRATION



Exhibit & Poster Hall Information

Exhibit Hall Hours


Friday, October 21, 10:00 – 16:00
Saturday, October 22, 10:30 – 14:00

Welcome Reception

Friday, October 21, 19:00 – 20:30

Poster Hours

Friday, October 21, 10:00 – 16:00
Saturday, October 22, 10:00 – 16:00



Exhibitor Listings & Booth

AMGEN.....	8	Foundation Medicine, Inc.....	10
ANGLE pic.....	9	Genentech.....	17
Bayer.....	11	Guardant.....	4
Biodesix.....	7	Lucence Health Inc.....	20 (located in Registration Area)
BioFluidica.....	3	Menarini Silicon Biosystems	15
Bio-Rad Laboratories	6	Natera, Inc.....	1
Boehringer Ingelheim	2	Novartis	18
BostonGene	14	Pfizer Oncology	16
Caris Life Sciences.....	13	Tempus.....	5
Exact Sciences.....	19	Tethis S.p.A.	12

Exhibitor Listing



Amgen | Booth #8
www.amgen.com

Amgen is a worldwide leader in biotechnology. For more than forty years, we've pursued some of the greatest challenges facing human health, marrying science and technological innovation with the passion of our staff, to serve patients and find new solutions that meet the growing demand for better quality healthcare for more people worldwide.



ANGLE plc | Booth #9
www.angleplc.com

ANGLE is a world-leading liquid biopsy company with offices in Guildford (UK), Toronto (Canada) and Greater Philadelphia (USA). ANGLE's Parsortix® PC1 Clinical System is the first FDA cleared medical device for the capture and harvest of intact circulating tumor cells from metastatic breast cancer patient blood for subsequent, user-validated analysis.



Bayer | Booth #11
www.bayer.us

Bayer is a global life sciences leader in healthcare and nutrition. Building on a 150-year legacy in healthcare, Bayer is committed to improving patient lives by developing therapies and delivering first-in-class educational and support programs to meet their needs.



Biodesix | Booth #7
www.biodesix.com

Our mission is to unite biopharma, physicians, and patients to transform the standard of care and improve outcomes with personalized diagnostics. We envision a world where all critical diseases are diagnosed early and treated quickly with the guidance of personalized diagnostic solutions, so humanity can thrive without the burden of disease.

Exhibitor Listing



BioFluidica | Booth #3

www.biofluidica.com

We are a privately held biotechnology company that has developed an automated liquid biopsy platform for isolating and enriching rare circulating cells (e.g., circulating tumor cells, CTCs) and exosomes. The platform is based on microfluidic chip devices having antibody surfaced micro-channels. These chips then serve as affinity “catch-and-release” to specifically enrich biomarkers of clinical or research interest from liquid biopsy.



Bio-Rad Laboratories | Booth #6

www.bio-rad.com

Bio-Rad is a global leader for life science research and clinical diagnostics that advance several applications for liquid biopsy. For assessing cfDNA and ctDNA in liquid biopsies, Droplet Digital PCR (ddPCR) offers unrivaled detection, precision, and absolute quantification. Celselect Slide™ Technology with the Genesis System enables CTC enrichment and enumeration applications.



Boehringer Ingelheim | Booth #2

www.boehringer-ingelheim.us

At Boehringer Ingelheim, we are taking cancer on. We are collaborating with the oncology community to deliver scientific breakthroughs to transform the lives of patients. Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer.



BostonGene | Booth #14

www.BostonGene.com

BostonGene's mission is to power healthcare's transition to personalized medicine using AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor Portrait™ Tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene Tumor Portrait™ Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient.



4TH ANNUAL CONGRESS
Liquid Biopsy
20 - 22 October 2022 | Miami, Florida

Full Congress Program
www.islb.info/congress-2022

Exhibitor Listing



Caris Life Sciences | Booth #13

www.carislifesciences.com

Caris Life Sciences® is the leading molecular science and technology company developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. Caris' suite of marketleading molecular profiling offerings assesses DNA, RNA and proteins, revealing a molecular blueprint helping physicians better detect, diagnose and treat patients.



**FOUNDATION
MEDICINE**

Foundation Medicine | Booth #10

www.foundationmedicine.com

Foundation Medicine's highly validated portfolio of comprehensive genomic profiling tests provides clinically-relevant genomic results for all advanced cancer patients regardless of specimen type. Find out more about the first FDA-approved test for solid tumors, our liquid biopsy for solid tumors, and our test for hematologic malignancies at foundationmedicine.com/genomic-testing.

**EXACT
SCIENCES**

Exact Sciences | Booth #19

www.precisiononcology.exactsciences.com/about-us

Genentech

A Member of the Roche Group

Genentech | Booth #7

www.gene.com

For more than 40 years, we've been following the science, seeking solutions to unmet medical needs. As a proud member of the Roche Group, we make medicines to treat patients with serious medical conditions. We are headquartered in South San Francisco, California.



4TH ANNUAL CONGRESS
Liquid Biopsy
20 - 22 October 2022 | Miami, Florida

Full Congress Program
www.islb.info/congress-2022

Exhibitor Listing

United States and Singapore



Guardant | Booth #4

www.guardanthealth.com

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum.



Lucence Health Inc. | Booth #20

www.lucence.com

Lucence is a precision oncology company committed to bringing clarity to cancer care. Lucence makes ultrasensitive liquid biopsy tests to provide doctors and their patients life-changing information to enable earlier detection and effective treatment. Headquartered in Palo Alto, Lucence supplies personalized cancer care services through twin CLIA-licensed laboratories in the



Menarini Silicon Biosystems | Booth #15

www.siliconbiosystems.com

Menarini Silicon Biosystems offers the new CELLSEARCH® Circulating Multiple Myeloma Cell (CMMC) Enumeration assay, the first-of-its-kind LDT, which directly measures levels of plasma cells in peripheral blood. The CELLSEARCH® CMMC enumeration test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, the test serially monitors plasma cell burden over time without requiring repeated bone marrow biopsies. Through our groundbreaking technology platforms and global lab services, we have standardized serial monitoring through cell-based liquid biopsy for a variety of conditions.



Natera | Booth #1

www.natera.com

Signatera™
Residual disease test (MRD)

Signatera is a personalized, tumor-informed ctDNA assay for molecular residual disease (MRD) detection and treatment response monitoring in patients previously diagnosed with cancer. Signatera is optimized to detect low levels of ctDNA, to help stratify high risk patients and optimize patient management. Discover more at: www.natera.com/oncology/



4TH ANNUAL CONGRESS

Liquid Biopsy

20 - 22 October 2022 | Miami, Florida

Full Congress Program

www.islb.info/congress-2022

Exhibitor Listing

signatera-advanced-cancer-detection

that challenge the most feared diseases of our time.



Novartis | Booth #18

www.novartis.com

Novartis Corporate Descriptor Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 145 nationalities work at Novartis around the world.



Pfizer Oncology | Booth #16

www.pfizer.com

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures

"TEMPUS

Tempus | Booth #5

www.tempus.com

Data-driven precision medicine. Bringing the power of data and artificial intelligence to healthcare.



Tethis S.p.A. | Booth #12

www.tethis-lab.com

Tethis S.p.A. introduces automation and standardization in the pre-analytical phase of liquid biopsy for cancer diagnostics through its proprietary platform See.d and SBS nanocoated slides, providing the highest quality and integrity of liquid biopsy specimens (plasma and cellular fraction), and enabling the exploitation of multi-biomarkers analysis for precise cancer management.



4TH ANNUAL CONGRESS

Liquid Biopsy

20 - 22 October 2022 | Miami, Florida

Full Congress Program

www.islb.info/congress-2022

Program at a Glance

TIME (GMT-4)	Thursday Oct 20	Friday Oct 21	Saturday Oct 22	TIME (GMT-4)
07:00				07:00
07:30				07:30
08:00		Industry Morning Session: Menarini Silicon Biosystems 08:00 – 08:45	Industry Morning Session: Natera 08:00 – 08:45	08:00
08:30				08:30
09:00		Track 1 - Basic Research in Liquid Biopsy 09:00 – 10:00	ISLB Awards Lectures 09:00 – 10:00	09:00
09:30				09:30
10:00		Exhibit & Coffee Break 10:00 – 10:30		10:00
10:30		Track 2 - Liquid Biopsy Clinical Application Challenges and Opportunities Worldwide 10:30 – 11:50	Industry Mid-Morning Session: Regeneron 10:15 – 10:45 Exhibit & Coffee Break 10:45 – 11:00	10:30
11:00			Track 5 - Expanding Clinical Application of Liquid Biopsy 11:00 – 12:10	11:00
11:30				11:30
12:00				12:00
12:30		Industry Lunch Session: Foundation Medicine 12:10 – 13:10	Industry Lunch Session: Guardant 12:30 – 13:30	12:30
13:00				13:00
13:30		Opening Ceremony & Inaugural Lecture 13:20 – 14:05	Exhibit & Coffee Break 13:30 – 14:15	13:30
14:00		Preferred Abstracts 14:05 – 15:05	Best Abstract Award & Invitation to ISLB 2023 14:15 – 14:45	14:00
14:30				14:30
15:00		Exhibit & Coffee Break 15:05 – 15:35	Track 6 - Translational Research in Liquid Biopsy 14:45 – 16:05	15:00
15:30	Multidisciplinary Stakeholder Workshop <i>Ticketed Session</i> 15:30 – 17:30	Track 3 - Current Clinical Application of Liquid Biopsy 15:35 – 16:45		15:30
16:00			Closing Remarks	16:00
16:30		Track 4 - Future of Liquid Biopsy 17:00 – 18:00		16:30
17:00				17:00
17:30				17:30
18:00	ISLB Meeting Other Societies 17:45 – 19:00	Industry Evening Session: Thermo Fisher 18:15 – 19:00		18:00
18:30				18:30
19:00	Career Development & Networking Cocktail 19:00 – 20:15	Welcome Reception 19:00 – 20:30		19:00
19:30				19:30
20:00				20:00
20:30				20:30

Full Congress Program

Thursday, October 20, 2022

15:30 - 17:30	<p>Multidisciplinary Stakeholder Workshop on Cancer Drug and Biomarker Development Location: Pan Am Ballroom See page 30 to visualize the Workshop details</p> <p>Panelists:</p> <p>Dr. Christopher Abbosh, AstraZeneca, United States Dr. Maria Arcila, Memorial Sloan Kettering Cancer Center, United States Dr. Burns Blaxall, Precision Health, United States Dr. Andres Cardona, Foundation for Clinical and Applied Cancer Research (FICMAC), Colombia Dr. David Gandara, University of California, Davis, United States Miss Allison Gittens, University of Maryland Greenebaum Cancer Center, United States Ms. Danielle Hicks, Go2 Foundation For Lung Cancer, United States Prof. Ola Khorshid, Nci Cairo Univeristy, Egypt Ms. Lesli Kiedrowski, Guardant Health, United States Dr. Natasha Leighl, Princess Margaret Cancer Centre, Canada Dr. Amy Moore, Lungevity Foundation, United States Miss Sarah Overton, Revenue Cycle, United States Dr. Geoff Oxnard, Foundation Medicine, United States Dr. Paz Polak, C2i Genomics, United States Dr. Jean-Francois Pouliot, Regeneron, United States Dr. Christian Rolfo, Mount Sinai Health System, United States Dr. Hillary Stires, Friends Of Cancer Research, United States Dr. Tabetha Sundin, AstraZeneca, United States Dr. Khaled Tolba, Foundation Medicine, United States Dr. Paz Vellanki, U.S. Food And Drug Administration, United States</p>
17:45 - 19:00	<p>ISLB meeting other Societies Location: Pan Am Ballroom</p> <p>Speakers:</p> <p>AMP - Dr. Maria Arcila, University Medical Center Hamburg-eppendorf, Germany IASLC - Dr. Karen Kelly, IASLC, United States FLASCO - Dr. Luis A. Raez, Memorial Can Institute/Florida International University, United States ISLA - Dr. Dana Connors, Foundation for the NIH, United States Bloodpac - Dr. Lauren Leiman, Bloodpac, United States MMOF - Prof. Ola Khorshid, NCI, Cairo University, Egypt ESLB - Dr. Klaus Pantel, Memorial Sloan Kettering Cancer Center, United State</p>
19:00 - 20:15	<p>Career Development Networking Reception Location: River Ends Patio</p> <p>A special event organized for networking with leaders in the field of liquid biopsies as well as with young investigators. We especially encourage early career participants to join us for this networking event which has been co-organized by the ISLB Young Committee.</p>

Full Congress Program

Friday, October 21, 2022

08:00 - 08:45	<p>ISS01 - CELLSEARCH® Circulating Multiple Myeloma Assay: A New Non-Invasive Liquid Biopsy Biomarker</p> <p>Location: Pan Am Ballroom</p> <p>Menarini Silicon Biosystems explains the new CELLSEARCH® Circulating Multiple Myeloma Cell (CMMC) Enumeration assay, the first-of-its-kind LDT, which directly measures levels of CD38+/CD138+/CD19-/CD45- plasma cells in one tube of peripheral blood. The CELLSEARCH® CMMC enumeration test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, the test serially monitors plasma cell burden over time without requiring repeated bone marrow biopsies, with data shown to correlate plasma cell genotypes. The new CellRescue™ tube provides 120 hours of stability at room temperature making sending samples to our CLIA certified lab in Pennsylvania easy.</p> <p>Speakers: Dr. Cameron Lilly, PhD, Scientific Affairs Liaison Dr. Frank Kuhr, PhD, Vice President of Medical Affairs</p> 
09:00 - 10:00	<p>Track 1 - Basic Research in Liquid Biopsy</p> <p>Location: Pan Am Ballroom</p> <p>Chair: Dr. Maria Jose Serrano, <i>University Hospital Virgen De Las Nieves</i>, Genyo, Spain Dr. Alessandro Russo, <i>Medical Oncology Unit, A.O. Papardo</i>, Messina, Italy</p>
09:00 - 09:10	<p>Miss Ariane Hallermayr, <i>MGZ - Medical Genetics Center</i>, Germany New Biological and Technological Approaches for Early Cancer Detection with ctDNA</p>
09:10 - 09:20	<p>Dr. Maria Jose Serrano, <i>University Hospital Virgen De Las Nieves</i>, Genyo, Spain Biological Changes in Tumor Cells Induced by Platelets</p>
09:20 - 09:30	<p>Dr. Massimo Cristofanilli, <i>Robert H. Lurie Comprehensive Cancer Center of Northwestern University</i>, United States Circulating Tumor Cell Cluster in Advanced Disease</p>
09:30 - 09:40	<p>Dr. Juan José Garcés, <i>Clínica Universidad de Navarra - CIMA</i>, Spain Winner ABSTRACT 2021 Congress Presentation</p>
	Discussion
10:00 - 10:30	<p>Exhibit and Coffee Break</p> <p>Location: Clipper Ballroom and Pre Function Spaces</p>

Full Congress Program

Friday, October 21, 2022

10:30 - 11:50	Track 2 - Liquid Biopsy Clinical Application Challenges and Opportunities Worldwide Location: Pan Am Ballroom Chair: Dr. Alessandro Russo , <i>Medical Oncology Unit, A.O. Papardo, Messina, Italy</i> Assoc. Prof. Edgardo Santos , <i>Genesis Care USA, United States</i>
10:30 - 10:40	Dr. Burns Blaxall , <i>The Christ Hospital, Cincinnati, United States</i> Challenges and Opportunities of Applying Liquid Biopsy on a Global Base
10:40 - 10:50	Prof. Ola Khorshid , <i>NCI, Cairo University, Egypt</i> Implementation of Liquid Biopsy in a Developing Country
10:50 - 11:00	Miss Sarah Overton , <i>PierianDx, United States</i> Dealing With Cost, Reimbursement and Co-pays in Liquid Biopsy
11:00 - 11:10	Dr. Paz Vellanki , <i>U.S. Food And Drug Administration, United States</i> Regulatory, Challenges and Opportunities From a Global Perspective
11:10 - 11:20	Dr. Amy Moore , <i>Lungevity Foundation, United States</i> What's Patients Really Need in Liquid Biopsy
11:20 - 11:30	Dr. Luis Raez , <i>Memorial Can Institute/Florida International University, United States</i> Cancer Disparities and Biomarkers Testing
	Discussion

Full Congress Program

Friday, October 21, 2022

12:10 - 13:10	<p>ISS02 - Implementing a Patient First Approach to Clinical Decision Making with Liquid and Tissue Biopsy Location: Pan Am Ballroom</p> <p>Liquid biopsy is a pragmatic and accessible technology for comprehensive genomic profiling and clinical decision making. This symposium will use patient cases to prompt discussion on the use of liquid biopsy in a “patient first” manner.</p> <p>Topics Include:</p> <ul style="list-style-type: none"> · The detection of challenging alterations, including fusions, using a DNA-based liquid biopsy approach · The complementary role of liquid and tissue biopsy · How liquid biopsy performance compares to tissue, what to do with a negative liquid biopsy and the growing utility of tumor fraction · Future monitoring approaches, including for immunotherapy <p>Speakers:</p> <p>Dr. Bruna Pellini, MD - Assistant Member and Thoracic Oncologist at <i>H. Lee Moffitt Cancer Center</i></p> <p>Dr. Umberto Malapelle, PhD - Chief Supervisor Predictive Molecular Pathology Laboratory at <i>University Federico II</i></p> <p>Dr. Geoff Oxnard, MD - Vice President, <i>Clinical Development</i>, Foundation Medicine</p> 
13:20 - 14:05	<p>Opening Ceremony & Inaugural Lecture Location: Pan Am Ballroom</p>
	<p>Chair: Prof. Christian Rolfo, <i>Icahn School Of Medicine, Center For Thoracic Oncology, Tisch Cancer Institute At Mount Sinai</i>, United States</p> <p>Welcome To ISLB</p>
	<p>Co-Chair: Dr. Luis Raez, <i>Memorial Can Institute/Florida International University</i>, United States</p> <p>Local Organizer Committee Introduction</p>
	<p>Speaker: Dr. David Gandara, <i>UC Davis Comprehensive Cancer Center</i>, United States</p> <p>ISLB Now and the Future</p>
	<p>Chair: Dr. Maria Jose Serrano, <i>University Hospital Virgen De Las Nieves</i>. Genyo, Spain</p> <p>Introduction to Inaugural Lecture</p>
	<p>Speaker: Dr. Massimo Cristofanilli, <i>Robert H. Lurie Comprehensive Cancer Center of Northwestern University</i>, United States</p> <p>Liquid Biopsy Advances in the Last Decade</p>

Full Congress Program

Friday, October 21, 2022

14:05 - 15:05	Preferred Abstracts Location: Pan Am Ballroom
Chairs: Mr. Diego De Miguel Perez , <i>Icahn School Of Medicine At Mount Sinai</i> , United States Dr. Aakash Desai , <i>Mayo Clinic</i> , United States	
Oral Presenters: Dr. Mohamed Gouda , United States Development and Validation of Tumor-Specific Methylation-Based Liquid Biopsy Assay for Detection of Non-Small Cell Lung Cancer Dr. Kasi Pashtoon M. , United States Liquid Biopsy (LBx)-based Comprehensive Genomic Profiling (CGP) Enables Detection of Diverse Pathogenic Fusion and Non-fusion Gene Rearrangements Dr. Pier Vitale Nuzzo , United States Cell-Free Methylated DNA (cfMeDNA) Immunoprecipitation and High Throughput Sequencing Technology (cfMeDIP-seq) for Early Detection of Colorectal Cancer (CRC) Discussant: Asst. Prof. Bruna Pellini , <i>H. Lee Moffitt Cancer Center And Research Institute/ University of South Florida</i> , United States	
Oral Presenters: Dr. Cristian Suárez Cabrera , Madrid BlaDimiR: A Urine-based miRNA score for Accurate Bladder Cancer Diagnosis and Follow-up Dr. Carolina Reduzzi , United States CK+/CD45+ CTCs and their Association with ctDNA Alterations in Breast Cancer Patients Discussant: Dr. Simon Heeke , <i>Ut Md Anderson Cancer Center</i> , United States	
Oral Presenters: Miss Róisín Daly , Ireland Extracellular Vesicles From the Cancer Liquid Biopsy: Is There a Compromise Between Perfect Vesicles and Routine Clinical Utility? Dr. Luis Raez , United States Using Liquid Biopsies First to make Front Line Treatment Decisions in Patients with Metastatic Non-small Cell Lung Cancer TBC Use of Liquid Biopsy (LBx) During the Diagnostic Odyssey of NSCLC: Time to Therapy in the Real-world Setting Discussant: Dr. Alessandro Russo , <i>Medical Oncology Unit, A.O. Papardo</i> , Messina, Italy, Italy	

Full Congress Program

Friday, October 21, 2022

15:05 - 15:35	Exhibit and Coffee Break Location: Clipper Ballroom and Pre Function Spaces
15:35 - 16:45	Track 3 - Current Clinical Application of Liquid Biopsy Location: Pan Am Ballroom
	Chair: Dr. David Gandara , <i>UC Davis Comprehensive Cancer Center</i> , United States
15:35 - 15:45	Dr. Natasha Leighl , <i>Princess Margaret Cancer Centre</i> , Canada How to Balance Next Generation Tumor Tissue Testing versus Liquid Biopsy Algorithms in the Clinic
15:45 - 15:55	Assoc. Prof. Nicola Fusco , <i>European Institute Of Oncology, IEO, IRCCS</i> , Italy Liquid Biopsy in Breast Cancer: A Moving Target
15:55 - 16:05	Dr. Heinz Josef Lenz , <i>USC Norris Comprehensive Cancer Center</i> , United States Colorectal Cancer - Opportunities for Liquid Biopsy
16:05 - 16:15	Dr. Joshua Lang , <i>Biomedical Research, Department of Medicine</i> , Carbone Cancer Center Clinical Application of Liquid Biopsies in Urologic Cancers
16:15 - 17:15	Dr. David Gandara , <i>UC Davis Comprehensive Cancer Center</i> , United States Convergence of Precision Medicine and Liquid Biopsy in NSCLC
	Discussion

Full Congress Program


Friday, October 21, 2022

17:00 - 18:00	Track 4 - Future of Liquid Biopsy Location: Pan Am Ballroom Chairs: Assoc. Prof. Eloísa Jantus-Lewintre , <i>Universitat Politècnica De València</i> , Spain Dr. Luis Raez , <i>Memorial Can Institute/Florida International University</i> , United States
17:00 - 17:10	Dr. Manel Esteller , <i>Josep Carreras Institute</i> , Barcelona, Spain, Cancer Screening. Detection of Cancer Using Cell-Free DNA Methylation
17:10 - 17:20	Dr. Adam Widman , <i>Memorial Sloan Kettering Cancer Center</i> , United States Machine Learning for Cancer Detection and Monitoring Using Liquid Biopsies
17:20 - 17:30	Dr. Natasha Leighl , <i>Princess Margaret Cancer Centre</i> , Canada Redefining CtDNA Endpoints in Perioperative Clinical Trials
17:30 - 17:40	Dr. Jillian Phallen , <i>Johns Hopkins University School Of Medicine</i> , United States Fragmentomics of Cell-free DNA in Liquid Biopsies
	Discussion
18:15 - 19:00	ISS03 - Novel Applications of Liquid Biopsies in Biliopancreatic Cancer and NSCLC Location: Pan Am Ballroom Part 1 Section Title: Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures Part 2 Section Title: Clinical application of 72-hour blood-based next generation sequencing in patients with newly diagnosed non-small cell lung cancer Questions - Questions & Answers Speakers: Dr. Matías A. Ávila , Professor of <i>Biochemistry at the University of Navarra School of Medicine</i> , and Director of the <i>Hepatology Program of the Center for Applied Medical Research (CIMA)</i> Miss Leona Hamrick DHSc , PA-C, MSL-BC, Vice President of <i>Clinical Development and Medical Affairs at Biodesix</i>
19:00 - 20:30	Welcome Reception Location: Clipper Ballroom and Pre Function Spaces

ThermoFisher
SCIENTIFIC

Full Congress Program

Saturday, October 22, 2022

08:00 - 08:45	<p>ISS04 - A New Era: ctDNA to Guide Management of Solid Tumors</p> <p>Location: Pan Am Ballroom</p> <p>Description: ctDNA analysis for residual disease assessment has evolved as a powerful adjunct tool to help clarify the clinical pathway when managing patients with solid tumors. Which patients should get adjuvant treatment? Is there a more reliable tool to monitor my at-risk patients? Join us as we take a closer look at the expanding data and what this could mean to help answer common clinical questions and optimize patient management.</p> <p>Speakers: Dr. Adham Jurdi, MD- Medical Oncologist, GI Malignancies, Medical Director, Oncology, Natera</p> <p> Signatera™ Residual disease test (MRD)</p>
09:00 - 10:00	<p>ISLB Awards Lectures</p> <p>Location: Pan Am Ballroom Chairs: ISLB Executive Board</p>
09:00 - 09:30	<p>Prof. Caroline Dive, <i>CRUK Manchester Institute</i>, United Kingdom ISLB Lifetime Achievement Award: Liquid Biopsies in Lung Cancer - Detection, Subtyping and Disease Monitoring</p>
09:30 - 10:00	<p>Dr. Maximilian Diehn, <i>Stanford University</i>, United States ISLB Research Award</p>

Full Congress Program

Saturday, October 22, 2022

10:15 - 10:45	<p>ISS05 - Addressing Current and Future Challenges with PD-L1 IHC Assays Utilized to help Guide NSCLC Treatment</p> <p>Location: Pan Am Ballroom</p> <p>Multiple PD-L1 immunohistochemistry (IHC) assays have been developed for various checkpoint inhibitors targeting the programmed cell death-1 (PD-1/PD-L1) axis but lack of harmonization has created complexity for clinicians in interpretation of clinical trial data. This is a first-of-its kind bridging study in advanced non-small cell lung cancer (NSCLC) demonstrating concordance of two PD-L1 IHC assays using samples from patients treated with first-line cemiplimab in EMPOWER-Lung 1</p> <p>Speakers: Dr. Jean-Francois Pouliot</p> <p>REGENERON <i>science to medicine®</i></p>
10:45 - 11:00	<p>Exhibit and Coffee Break</p> <p>Location: Clipper Ballroom and Pre Function Spaces</p>
11:00 - 12:10	<p>Track 5 - Expanding Clinical Application of Liquid Biopsy</p> <p>Location: Pan Am Ballroom</p> <p>Chairs: Prof. Christian Rolfo, Icahn School Of Medicine, Center For Thoracic Oncology, Tisch Cancer Institute At Mount Sinai, United States Dr. Natasha Leigh, Princess Margaret Cancer Centre, Canada</p>
11:00 - 11:10	<p>Assoc. Prof. Valsamo Anagnostou, Johns Hopkins University, United States Dynamics of ctDNA and Other Biomarkers for Immunotherapy</p>
11:10 - 11:20	<p>Dr. Maximilian Diehn, Stanford University Bronchoalveolar Lavage as a New Source of Liquid Biopsy</p>
11:20 - 11:30	<p>Dr. Fred Hirsch, Mount Sinai School of Medicine Integration of New Tissue Technologies with Liquid Biopsy in Immunotherapy</p>
11:30 - 11:40	<p>Assoc. Prof. Triparna Sen, Icahn School Of Medicine At Mount Sinai Departing from Animal Models to Clinical Applications: the Future of Biomarkers</p>
11:40 - 11:50	<p>Prof. Caroline Dive, CRUK Manchester Institute Cancer Interception Through Liquid Biopsy</p>

Full Congress Program

Saturday, October 22, 2022

12:30 - 13:30	<p>ISS06 - Clinical Applications of Liquid Biopsy Location: Pan Am Ballroom</p> <p>Description: Presentation on clinical uses of liquid biopsy in lung, breast and colorectal cancer. Presentation and structured Q&A moderated by Dr Gandara</p> <p>Speakers: Dr. Ana Sandoval Leon, M.D., is a medical oncologist specializing in the treatment of breast cancer Dr. Georges Azzi is the director of Precision Medicine at the Cancer Center at Holy Cross Health in Fort Lauderdale</p> 
13:30 - 14:15	<p>Exhibit and Coffee Break Location: Clipper Ballroom and Pre Function Spaces</p>
14:15 - 14:45	<p>Best Abstract Award & invitation to ISLB 2023 Location: Pan Am Ballroom</p>
14:20 - 14:25	<p>Dr. Kenna Anderes, United States Clinical Validation of Plasma Cell-Free DNA (cfDNA) Sequencing in a Phase 2 Cohort of the KRYSTAL-1 Study of Adagrasib in Patients (pts) With KRASG12C-Mutated NSCLC</p>
14:25 - 14:30	<p>Discussion by Dr. David Gandara, UC Davis Comprehensive Cancer Center, United States</p>
14:30 - 14:35	<p>Dr. Simon Heeke, Ut Md Anderson Cancer Center, United States Asst. Prof. Bruna Pellini, H. Lee Moffitt Cancer Center And Research Institute/University of South Florida, United States Best Poster Award Presentation</p>
14:35 - 14:40	<p>Dr. Ola Khorshid, Medical Oncology Department at National Cairo University, Cairo, Egypt Dr. Nagla Abdel Karim, Schar Cancer Institute Dr. Rabab Gaafar Award for Young Researchers Presentation</p>
14:40 - 14:45	<p>Invitation to ISLB 2023</p>

Full Congress Program

Saturday, October 22, 2022

14:45 - 16:05	Track 6 - Translational Research in Liquid Biopsy Location: Pan Am Ballroom
	Chairs: Assoc. Prof. Eloísa Jantus-Lewintre , <i>Universitat Politècnica De València</i> , Spain TBC
14:45 - 14:55	Dr. Maria Arcila , <i>Memorial Sloan Kettering Cancer Center</i> , United States Controversy Session: RNA Based Analysis in Liquid Biopsy - PROS
14:55 - 15:05	Dr. Ignacio Wistuba , <i>MD Anderson Cancer Center</i> , United States Controversy Session: RNA Based analysis in Liquid Biopsy - CONS
15:05 - 15:15	Prof. Alberto Bardelli , <i>University Of Turin, Dept Of Oncology</i> , Turin, Italy Innovative Clinical Trial Design
15:15 - 15:25	Prof. Christian Rolfo , <i>Icahn School Of Medicine, Center For Thoracic Oncology</i> , Tisch Cancer Institute At Mount Sinai, United States Pitfall in Early Detection by Using Liquid Biopsy: The Time to Improve
15:25 - 15:35	Assoc. Prof. Eloísa Jantus-Lewintre , <i>Universitat Politècnica De València</i> , Spain Role of Liquid Biopsy in Cancer Monitoring
15:35 - 15:45	Assoc. Prof. Umberto Malapelle , <i>University of Naples Federico II</i> , Italy Bidimensional Liquid Biopsy Analysis: Integration of DNA and RNA Data

ISLB Awards Lectures

Saturday, October 22, 2022

Time: 09:00 – 10:00

Location: Pan Am Ballroom

Awardees



Prof. Caroline Dive

Interim Director CRUK Manchester Institute,
United Kingdom

Award:

ISLB Lifetime Achievement Award

Presentation title:

Liquid Biopsies in Lung Cancer - Detection, Subtyping
and Disease Monitoring



Dr. Maximilian Diehn

Professor Stanford University,
United Kingdom

Award:

ISLB Research Award



Official Networking Events



Welcome Reception

After 2 years of virtual meetings, we are so excited to welcome you in person to Miami. Kick off ISLB 2022 with a time of networking over drinks and passed canapes. Join fellow congress delegates as we welcome the next few days of exciting presentations, posters, and exhibition.

October 21

Exhibit Hall (Clipper Ballroom and Pre Function Spaces)
19:00 – 20:30

**Congress badge or event ticket required for entry*

Multidisciplinary Stakeholder Workshop on Cancer Drug and Biomarker Development

Thursday, October 20, 2022

Time: 15:30 – 17:30

Location: Pan Am Ballroom

**pre registration and payment required*

Panel 1: Global Access to Molecular testing of Cancer: Role of Liquid Biopsy (LB)

CHAIR: David Gandara

Co-chair: Eloisa Jantus

Panelists: Paz Polak (C2i Genomics), Natasha Leigh (Canada) Hillary Stires (FOCR), Andres Cardona (Columbia), Amy Moore (Lungevity), Ola Khorshid (NCI Cairo), Sara Overton (Revenue Cycle)

Panel 2: Implementation of LB in clinical setting

CHAIR: Christian Rolfo

Co-chair: Umberto Malapelle

Panelists: Paz Vellanki (FDA), Danielle Hicks (GO2), Leslie Kiedrowski (Guardant), Allison Gittens (Maryland), Khaled Tolba (Foundation M), Burns Blaxall (Precision Health)

Panel 3: Integration of LB in clinical trials and translational research

CHAIR: Luis Raez

Co-chair: Estelamari Rodriguez

Panelists: Paz Vellanki (FDA), David Gandara, Jean Francois Pouliot, Tabettha Sundin (AZ), Geoff Oxnard (Foundation M), Christian Rolfo, Paz Polak (C2i Genomics), Dr. Christopher Abbosh (AstraZeneca)

Description:

This workshop will provide the opportunity for an open and interactive discussion between Pharma representatives, the healthcare team, patient advocates together with regulatory, statistical, and reimbursement experts.



Posters

PP: Poster available in person and digitally on the Virtual Platform

DP: Poster available digitally only

PP.02

A Novel, Automated Approach Providing Standardized Sample Preparation for Multiple Liquid Biopsy Analyses
Dr. Grazyna Elzbieta Stepień

PP.03

Amplicon-Based Liquid Biopsy Platform Complements Tissue Genotyping in Detection of Guideline-Recommended Biomarkers in Metastatic NSCLC
Dr. Richa Dawar

PP.04

Innovative Public Procurement in Liquid Biopsy: A Public Initiative to Implement New Technologies in the Andalusian Health System
Dr. María Jose Serrano

PP.05

An Integrated Microfluidic System for Simultaneous Isolation of CTCs and CTC Clusters
Prof. Majid Ebrahimi Warkiani

PP.06

The Prognostic and Predictive Value of Circulating Tumor Cells and Urinary Tumor Cells in Bladder Cancer
Dr. Elvira Famulari

PP.09

Analytical Validation and Performance of the Oncomine™ Dx Express CE-IVD NGS Liquid Biopsy Assay for Non-Small Cell lung cancer
Mr. Jeoffrey Schageman

PP.10

Collaborative Meta-analytical Approaches to Advance the Use of ctDNA in Clinical Cancer Research: The Friends of Cancer Research ctMoniTR Project
Dr. Hillary Stires

PP.11

Personalized Circulating Tumor DNA(ctDNA)-Guided Tumor Response Monitoring in Patients With Deficient Mismatch Repair (dMMR) Gastrointestinal (GI) Tumors Receiving Immunotherapy (IO)
Dr. Sakti Chakrabarti

PP.12

Novel, Accurate and Non-invasive Tool for BCG-Response Prediction in Bladder Cancer Based on Mirnas Detection in Urine
Dr. Marta Dueñas Porto

PP.13

Exosomal miRNA-574-5p and miRNA-181a-5p as Prognostic Markers in Advanced Non-small Cell Lung Cancer Patients Treated With Nivolumab
Asst. Prof Carlo Genova

PP.14

Prognostic Role of Circulating PD-L1, B7H3 and B7H4 in Advanced Non-Small Cell Lung Cancer Patients Treated with Immunotherapy
Asst. Prof Carlo Genova

PP.15

ARID1A Alterations as Positive Predictors of Immune Checkpoint Inhibitor Efficacy in Advanced Non-small Cell Lung Cancer: Real World Data Analysis
Ms. Caroline Weipert

PP.16

Analysis of TCR-β Repertoire Analysis to Identify Predictive and Prognostic Biomarkers in Non-Small Cell Lung Cancer Patients Treated with Anti-PD1
Miss Susana Torres Martínez

PP.17

Assessment of CD5 and CD6 Expression Levels in PBMCs as Potential Biomarkers in Advanced-stage NSCLC Patients Treated with Immunotherapy
Miss Susana Torres Martínez

PP.18

The Evolution of “Liquid Biobanking”: Ten-year Experience of a Large European Cancer Center
Dr. Giuseppina Bonizzi

Posters

PP: Poster available in person and digitally on the Virtual Platform

DP: Poster available digitally only

PP.19

Rapid Molecular Characterization of Newly Detected Lung Cancer in Hospitalized Patients With Next Generation Sequencing (NGS) Through Up-Front Liquid Biopsy

Asst. Prof Carlo Genova

PP.21

Detection of PI3KCA Gene Mutations by NGS in Cell-free DNA in Patients with a Clinical Diagnosis of PROS Syndrome

Dr. Eloísa Jantus-Lewintre

PP.22

Plasma Cell-Free DNA Methylation As Biomarker for Hepatocellular Carcinoma

Dr. Maria Arechederra

PP.24

Utility of Circulating Tumor DNA (ctDNA)-Based Tumor Genomic Profiling in Patients With Carcinoma of Unknown Primary (CUP)

Dr. Sakti Chakrabarti

PP.25

Evaluation of the Circulating Tumor DNA as a Biomarker for Prognosis and Treatment Monitoring in Patients With Metastatic Breast Cancer

Dr. Ricardo Chinchilla-Monge

PP.26

High Plasma and Tissue TMB Predicts Better Outcomes in Patients With Resected Malignant Pleural Mesothelioma

Dr. Christian Rolfo

PP.27

Assessing the Quality of cfDNA Somatic Variant Testing in Clinical Practice

Prof. Zandra Deans

PP.28

Liquid Biopsy for the Management of NSCLC Patients: A Real World Single Institution's Experience

Dr. Marzia Del Re

PP.29

Cell Free HPV DNA has High Diagnostic Accuracy for HPV-associated Head and Neck Cancers at the Time of Presentation

Dr. Daniel Faden

PP.30

Extensive Genomic Characterization in Early Breast Cancer (EBC) Through Circulating Tumor DNA (ctDNA): a Pilot Study

Dr Carolina Reduzzi

PP.31

Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitors Beyond Progression in Metastatic Breast Cancer: Role of Circulating Tumor DNA Characterization

Dr Carolina Reduzzi

PP.32

Circulating Tumor DNA (ctDNA) Identifies Patients at Risk for Recurrence in Resected, Early-Stage Non-small Cell Lung Cancer (ICON Project)

Dr. Simon Heeke

PP.33

Development of a mRNA Signature in Plasma for Discrimination of Tumor vs. Benign Pulmonary Nodules

Dr. Clara Mayo de las Casas

PP.34

Rapid Detection of EGFR, KRAS and BRAF Hotspot Mutations Present in ctDNA Isolated From Cancer Patient's Liquid Biopsies

Miss Irina Palacin Aliana

PP.35

Comparison of Two Next-Generation Sequencing Platforms for ctDNA Analysis in Non-small Cell Lung Cancer Patients

Dr. Francesco Pepe

Posters

PP: Poster available in person and digitally on the Virtual Platform

DP: Poster available digitally only

PP.36

The Prognostic Value of Circulating Tumor DNA in Triple Negative Breast Cancer Patients with Incomplete Response to Neoadjuvant Chemotherapy

Miss Talia Roseshter

PP.37

Detection of Potentially Pathogenic Alterations in Circulating Cell-Free DNA Derived from Plasma of Brain Tumor Patients

Ms. Paulina Szadkowska

PP.38

Lasofloxifene Reduced ESR1 Mutant Allele Fraction and Provided Clinical Benefit Versus Fulvestrant in Metastatic Breast Cancer: The ELAINE 1 Trial

Dr. Massimo A Cristofanilli

PP.39

Utility of Liquid Biopsy Monitoring in EGFR-mutated NSCLC Patients Treated in first-line with Osimertinib

Miss Susana Torres Martínez

PP.40

Maximizing Clinical Utility of Liquid Biopsy Utilizing a Single Blood Sample for ctDNA and CTC Analysis Using the Parsortix® System

Dr. Mariacristina Ciccioli

PP.41

Circulating Tumor Cells From Melanoma Patients Show Phenotypic Plasticity and Metastatic Potential in Xenograft NOD.CB17 Mice

Dr. Claudia Felici

PP.42

Exploratory Analysis of Therapeutic Targets in Primary Cultures From Pleural and Ascitic Fluids of Cancer Patients

Dra Clara Mayo de las Casas

PP.43

The Impact of Cell-free Plasma DNA on Metastatic and Non-metastatic Prostate Cancer

Assoc. Prof Marwa Nabil

PP.44

High-Dimensional Phenotypic Characterization of Circulating Tumor Cells From Prostate Cancer Patients by Time-of-Flight Mass Cytometry (CyTOF)

Miss Alba Rodríguez-Martínez

PP.45

EV miRNA-30c Inhibits Chemoradiation-Induced Autophagy and Is a Good Predictive Biomarker for Outcome in Patients With Locally Advanced NSCLC

Mr. Diego De Miguel Perez

PP.46

Sequencing of Exosomal miRNAs in Breast Cancer to Understanding the Functional Pathways Involved In Cancer Evolution

Miss Coral González-Martínez

PP.47

sGalectin-3, sIL-10, sMIP3a and sIL13 as Prognostic Biomarkers in Triple-negative Breast Cancer

Miss Susana Torres Martínez

PP.48

Soluble Immune-related Factors are Associated with Response to Neoadjuvant Chemotherapy in Triple-negative Breast Cancer

Miss Susana Torres Martínez

DP.01

Bowel Preparation for Colonoscopy Changes Serum Composition: Pre-analytical Potential Flaw for Diagnosis as Detected by Thermal Liquid Biopsy (TLB)

Prof. Olga Abian

DP.02

Microfluidic Amperometric Immunosensor Based on Porous Nanomaterial Towards CLAUDIN7 Determination for Colorectal Cancer Diagnosis

Dr. Francisco Gabriel Ortega Sánchez

DP.03

Do GWAS-Identified Risk Variants for Chronic Lymphocytic Leukemia Influence Disease Progression?

Mr. Antonio José Cabrera Serrano

Posters

PP: Poster available in person and digitally on the Virtual Platform

DP: Poster available digitally only

DP.04

GWAS-identified variants for obesity do not influence the risk of developing multiple myeloma: a population-based study and meta-analysis

José Manuel Sanchez-Maldonado

DP.05

Do GWAS-Identified Risk Variants for Chronic Lymphocytic Influence Overall Patient Survival?

Mr. Antonio José Cabrera Serrano

DP.06

Application of Liquid Biopsy: Detection of Genomic Biomarkers for the Treatment of Patients With Stage IV NSCLC. Italian Multicentre Experience.

Dr. Antonio Lugini

DP.09

Differential Presence of Exons (DPE). New Method Based on Ngs-Liquid Biopsy in Colorectal Cancer

Mr. David Rubio Mangas

DP.10

SLFN11 Methylation in Plasma Cell-Free DNA in Metastatic NSCLC and Metastatic HNSCC Patients under immunotherapy

Miss Victoria Tserpeli

DP.11

Liquid Biopsy in Prostate Cancer Patients: Variant Analysis on Homologous Recombination Repair System in Association to Shallow WGS

Dr. Alessandra Virga

DP.12

Potential Use of ExoDNA to Detect Prognostic and Predictive Biomarkers in HR+/HER2- Metastatic Breast Cancer

Dr. Vanesa García-Barberán

DP.13

The Role of ctDNA and exoDNA in Skin Tumor Patients: a Pilot Study

Asst. Prof Pasquale Pisapia

DP.14

Platelets-Tumor Cells Interaction: A Shield Against Chemotherapy

Mr. Jorge Cerón-Hernández

DP.15

Circulating Tumor Cells and Platelets-derived AR-V9 as Monitoring Tool for Prostate Cancer

Dr. Carmen Garrido Navas

DP.16

Comparison of Methods of Isolation and Quantification of Cell Free DNA From Plasma of Patients With Breast Cancer

Miss Asiyah Bukhari

DP.17

Monitoring Treatment Response Through Liquid Biopsy in Patients With Breast Cancer

Ms. Asiyah Bukhari

DP.18

Detection of Activating Mutations in Liquid Biopsy of Egyptian Breast Cancer Patients Using Targeted Next Generation Sequencing: A Pilot Study

Prof. Neemat Kassem

DP.19

Targeted Next Generation Sequencing Provides Insight for the Genetic Alterations in Liquid Biopsy of Egyptian Brain Tumor Patients

Prof. Neemat Kassem

DP.20

Cytokine Quantitative Trait Loci(cQTL) Genetic Variants for A.fumigatus Do Not Influence Risk of Developing Invasive Aspergillosis in High-Risk Hematological Patients

Ms. Ana Moñiz-Díez



See what's possible with
TAGRISSO



Explore more at TagrissoHCP.com



AstraZeneca
1800 Concord Pike, PO Box 15437, Wilmington, DE 19850-5437

TAGRISSO is a registered trademark of the AstraZeneca group of companies.
©2022 AstraZeneca. All rights reserved. US-69415 10/22





Join us in 2023 Madrid, Spain

Save the Date



ISLB
INTERNATIONAL SOCIETY
OF LIQUID BIOPSY



5TH ANNUAL CONGRESS

Liquid Biopsy

19 - 21 November 2023 | Madrid, Spain